AADC Gene Therapy for Advanced Parkinson's Disease: Interim Results of a Phase 1b Trial

被引：0
|
作者：
Ravina, Bernard [1 ]
Christine, Chadwick W. [2 ]
Larson, Paul S. [2 ]
Van Laar, Amber [3 ]
Richardson, R. Mark [3 ]
Kells, Adrian [1 ]
Boot, Brendon [1 ]
Martin, Alastair [2 ]
Thompson, Marin [2 ]
Bankiewicz, Krystof S. [2 ]
机构：
[1] Voyager Therapeut, Cambridge, MA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
来源：
MOLECULAR THERAPY | 2018年 / 26卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
63
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [1] Intraputaminal AADC gene therapy for advanced Parkinson's disease: Interim Results of a Phase 1b Trial
    Christine, Chadwick
    Bankiewicz, Krzysztoffs
    Van Laar, Amber
    Richardson, Mark
    Ravina, Bernard
    Kells, Adreian
    Boot, Brendon
    Martin, Alastair
    Thompson, Marin
    Larson, Paul
    NEUROLOGY, 2017, 89 (08) : E99 - E99
  • [2] Intraputaminal AADC gene therapy for advanced Parkinson's disease: interim results of a phase 1b Trial
    Ravina, B.
    Christine, C.
    Bankiewicz, K.
    Van Laar, A.
    Richardson, M.
    Kells, A.
    Boot, B.
    Martin, A.
    Thompson, M.
    Larson, P.
    HUMAN GENE THERAPY, 2017, 28 (12) : A6 - A6
  • [3] VY-AADC01 gene therapy in Parkinson's disease: Interim results of the on-going Phase 1b PD-1101 trial
    Larson, P.
    Bankiewicz, K.
    Van Laar, A.
    Richardson, R.
    Ravina, B.
    Kells, A.
    Boot, B.
    Martin, A.
    Thompson, M.
    Christine, C.
    MOVEMENT DISORDERS, 2018, 33 : S137 - S138
  • [4] Intraputaminal AADC gene therapy for Parkinson's disease: Results of a phase 1 study
    Aminoff, M. J.
    Christine, C. W.
    Starr, P. A.
    Larson, P. S.
    Eberling, J. L.
    Jagust, W. J.
    Hawkins, R. A.
    VanBrocklin, H. F.
    Bankiewicz, K. S.
    MOVEMENT DISORDERS, 2009, 24 : S254 - S255
  • [5] Early results from a clinical trial of AADC gene therapy for Parkinson's disease
    Eberling, JL
    Bankiewicz, KS
    McGuire, D
    Aminoff, M
    Christine, C
    Starr, P
    Larson, P
    Jagust, WJ
    NEUROLOGY, 2006, 66 (05) : 276 - 277
  • [6] Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease
    Christine, Chadwick W.
    Bankiewicz, Krystof S.
    Van Laar, Amber D.
    Richardson, R. Mark
    Ravina, Bernard
    Kells, Adrian P.
    Boot, Brendon
    Martin, Alastair J.
    Nutt, John
    Thompson, Marin E.
    Larson, Paul S.
    ANNALS OF NEUROLOGY, 2019, 85 (05) : 704 - 714
  • [7] The PD-1102 trial in advanced Parkinson's disease: safety and clinical outcomes from a 3-year phase 1b study of AADC gene therapy administered via a posterior approach
    Factor, S.
    Gross, R.
    Van Laar, A.
    Christine, C.
    Larson, P.
    Kostyk, S.
    Lonser, R.
    Fine, E.
    Kwhaja, O.
    Li, C.
    Meier, A.
    Liang, G.
    Roberts, E.
    Richardson, R.
    MOVEMENT DISORDERS, 2021, 36 : S208 - S208
  • [8] Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
    Mittermeyer, Gabriele
    Christine, Chadwick W.
    Rosenbluth, Kathryn H.
    Baker, Suzanne L.
    Starr, Philip
    Larson, Paul
    Kaplan, Paul L.
    Forsayeth, John
    Aminoff, Michael J.
    Bankiewicz, Krystof S.
    HUMAN GENE THERAPY, 2012, 23 (04) : 377 - 381
  • [9] AADC gene therapy administered via a posterior approach: 18-month results from the PD-1102 trial in advanced Parkinson's disease
    Factor, S.
    Van Laar, A.
    Richardson, R.
    Christine, C.
    Larson, P.
    Kostyk, S.
    Lonser, R.
    Li, C.
    Liang, G.
    Meier, A.
    Fine, E.
    Gross, R.
    MOVEMENT DISORDERS, 2020, 35 : S395 - S395
  • [10] Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease
    Hwu, Paul Wuh-Liang
    Kiening, Karl
    Anselm, Irina
    Compton, David R.
    Nakajima, Takeshi
    Opladen, Thomas
    Pearl, Phillip L.
    Roubertie, Agathe
    Roujeau, Thomas
    Muramatsu, Shin-ichi
    EMBO MOLECULAR MEDICINE, 2021, 13 (09)
12345